Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Neuroscience 2 > Treatment Strategies for Multiple Sclerosis > Flashcards

Treatment Strategies for Multiple Sclerosis Flashcards

Discuss the main categories of treatments for MS Describe the phases of clinical trial development Discuss clinical trial evidence that supports disease modifying treatments for MS Critically evaluate the approved disease modifying treatments and the key aspects of their mechanisms, efficacy, and risks Discuss new treatments in the late stage of clinical development Critically evaluate potential approaches to preventing MS Discuss what a cure for MS should achieve

1
Q

What does the management of MS involve?

A

Education, counselling, managing acute attacks, preventing disease activity, symptomatic therapy, physical therapy, treating complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Give 2 causes of pseudo-relapses

A

Heat and fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the standard treatment for accelerating recovery from a relapse?

A

High-dose IV methylprednisolone (500-1000mg/day) for 3-5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does steroid treatment affect recovery from a relapse?

A

It makes it faster - but it does not affect the degree of recovery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is spasticity treated?

A

Stretching, physical therapy, and drugs including baclofen, tizanidine, and benzodiazepines. In severe cases, botulinum toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What causes spasticity in MS?

A

Damage to the corticospinal tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is paroxysmal pain in MS treated?

A

Gabapentin (900mg-1.8g/day) or carbamazepine (100-800mg/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is chronic dysaesthetic pain (pain when touched due to nerve damage) treated in MS?

A

Amitriptyline 20-100mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is fatigue treated in MS?

A

Lifestyle advice to save energy (regular sleep pattern, day planning), occasionally drugs (amantadine, modafinil, some antidepressants)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is mobility impairment treated in MS?

A

Physiotherapy, encouraging light activity, functional stimulation, orthotics and mobility aids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the aims of treatment of primary progressive MS?

A

Suppressing relapses, preventing disease progression, preventing new white matter lesions, reducing the rate of brain atrophy, and preventing conversion to secondary progressive MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Name at least 3 disease-modifying treatments approved for relapsing-remitting MS

A

Teriflunomide, interferon beta-1a, interferon beta-1b, daclizumab, peginterferon beta-1a, ocrelizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Name a disease-modifying treatment approved for secondary progressive MS

A

Interferon beta, mitoxantrone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name a disease-modifying treatment approved for primary progressive MS

A

Ocrelizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Give a randomised controlled trial endpoint in a study of relapsing-remitting MS

A

Annualised relapse rate, proportion of relapse-free patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Give a randomised controlled trial endpoint in a study of secondary progressive MS

A

Time to progression of disability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Give a randomised controlled trial endpoint in a study of clinically isolated syndrome

A

Time to second attack

18
Q

What is the first line injectable drug for relapsing-remitting MS?

A

Interferon beta - either interferon-beta1a or interferon-beta1b

19
Q

Describe the effect of interferon beta on MS

A

Reduces T cell activation, reduces secretion of IFN-gamma, IL-12, and TNF, modulates the blood-brain barrier by inhibiting interaction between VLA-4 on T cells and VCAM-1 on endothelial cells

20
Q

How is interferon beta administered?

A

IM or SC injection

21
Q

What are the side effects of interferon beta?

A

Reactions at the injection site, flu-like symptoms, depression, elevated liver function tests

22
Q

What is glatiramer acetate?

A

A 4 amino acis synthetic co-polymer based on myelin basic protein

23
Q

How does glatiramer acetate mofidy disease in MS?

A

It binds to HLA-DR2, inhibitits myelin basic protein reactice cells, and shifts cytokines to an anti-inflammatory phenotype

24
Q

How is glatiramer acetate administered?

A

Daily or 3x week SC injections

25
Q

What is fingolimod?

A

An agonist at the S1P1 receptors on T cells

26
Q

How does fingolimod reduce disease activity in MS?

A

It keeps lymphocytes in the lymph nodes by interfering with T cell trafficking

27
Q

How does fingolimod compare to IFN-beta 1a?

A

Significantly more affective at reducing the annualised relapse rate, even in highly active MS

28
Q

What are the side effects of fingolimod?

A

Opportunistic infections, skin cancers, elevated liver enzymes, lymphopaenia, macular oedema, hypertension, dyspnoea, bronchitis, diarrhoea, cardiac effects

29
Q

Why is fingolimod only licensed in highly-active relapsing-remitting MS?

A

Extensive side effects profile, necessity for 12 month monitoring with CT

30
Q

What are the side effects of dimethyl fumarate?

A

Flushing, nasopharyngitis, headache, diarrhoea, UTI, URTI, nausea, fatigue, back pain, upper abdominal pain, proteinuria

31
Q

How does teriflunomide reduce disease activity in MS?

A

It decreases the proliferation of T and B autoreactive lymphocytes

32
Q

Why is frequent blood monitoring required for patients on teriflunomide?

A

Raised ALT

33
Q

Which patient group is teriflunomide prescribed in?

A

Those who cannot tolerate dimethyl fumarate due to severe GI side effects

34
Q

What are the highest efficacy drugs for MS?

A

Monoclobal antibodies

35
Q

How does natalizumab reduce disease activity in MS?

A

Binds to lymphocytes and prevents their adhesion to VCAM receptors on endothelial cells of the blood brain barrier, so they cannot enter and form lesions

36
Q

Why do patients require counselling before receiving natalizumab?

A

Rarely, it lead to JC virus infection and progressive multifocal leukoencephalopathy, which causes oligodendrocyte death and patient death. There is no treatment

37
Q

Which patient group can be treated with natalizumab?

A

Those with highly-active MS which has not responded to treatment, or young-onset patients with highly active disease at high risk of early secondary progression

38
Q

Describe the presentation of progressive multifocal leukoencephalopathy

A

Progressive and rapid (weeks) deterioration of cognitive function, behaviour, and language with hemiparesis and seizures

39
Q

What is alemtuzumab?

A

A humanised monoclonal antibody that selectively targets CD52 positive T and B lymphocytes and works as an induction therapy

40
Q

What are the side effects of alemtuzumab?

A

Infusion reactions, opportunistic infections, reactive autoimmunity (Graves’ disease in up to 50%, immune thrombocytopaenic purpura, Goodpasture’s syndrome)

41
Q

What is ocrelizumab?

A

A humanised monoclonal antibody against CD20 positive B lymphocytes

42
Q

Why is haematopoeitic stem cell transplantation not yet approved for MS?

A

It has a mortality of around 2%, whereas MS is not usually life-threatening

Neuroscience 2 (30 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions